RTN2 (Reticulon 2), also known as Nogo, is a member of the reticulon family of membrane proteins with critical roles in shaping the endoplasmic reticulum (ER) network and inhibiting axonal regeneration in the central nervous system. RTN2 is best known for its potent inhibitory effects on neural repair following injury, making it a key molecule in spinal cord injury and neurodegenerative disease research[1][2].
| Property | Value |
|---|---|
| Gene Symbol | RTN2 |
| Full Name | Reticulon 2 (Nogo) |
| Aliases | Nogo, NOGO-A, RTN2-A, Reticulon-2 |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 10228 |
| OMIM | 604215 |
| Ensembl ID | ENSG00000155050 |
| UniProt | Q9NQC3 |
| Gene Type | Protein Coding |
The RTN2 gene produces multiple isoforms through alternative splicing[3]:
N-terminus [Nogo-specific domain] --- [Reticulon homology domain] C-terminus
| |
+-- Nogo-66 receptor binding +-- Amphipathic helices
+-- Amino-Nogo domain +-- ER morphology
Reticulon proteins are essential for shaping the tubular ER network[4][5]:
In the nervous system, RTN2 performs additional specialized functions:
RTN2 is expressed in:
In ALS, RTN2 dysregulation contributes to motor neuron pathology[2:1]:
Reticulons have been implicated in AD pathogenesis:
In demyelinating diseases and injury:
Reticulons have been linked to protein aggregation in neurodegeneration[7]:
| Approach | Stage | Mechanism | Reference |
|---|---|---|---|
| Anti-Nogo-A antibodies | Clinical trials | Block Nogo-A inhibitory activity | [1:1] |
| NgR1 antagonists | Preclinical | Block receptor-ligand interaction | [8] |
| Small molecule inhibitors | Research | Inhibit Nogo signaling | [9] |
| Gene therapy | Preclinical | Silence Nogo expression | [9:1] |
| Protein | Interaction | Function |
|---|---|---|
| NgR1 (RGT) | Receptor | Nogo-66 receptor, mediates inhibition |
| Troy/TAJ | Receptor | TROY receptor, mediates inhibition |
| Lingo-1 | Co-receptor | Complex component with NgR1 |
| RTN1 | Family | Reticulon family member |
| RTN3 | Family | Reticulon family member |
| RTN4 (Nogo-B) | Family | Reticulon family member |
Schwab ME, Strittmatter SM. Nogo and neural regeneration. Nature Reviews Neuroscience. 2014. ↩︎ ↩︎
Chiurchiù V,表服部, E, et al. Reticulon proteins in neurodegenerative diseases. Nature Reviews Neurology. 2016. ↩︎ ↩︎
Oertle T, Merkler D, Bregman T, et al. Nogo and the regeneration inhibitors: a gene family of neurite growth suppressors. Advances in Experimental Medicine and Biology. 2003. ↩︎
Voeltz GK, Prinz WA, Shibata Y, Rist JM, Rapoport TA. A tubular membrane network that connects ER to Golgi and influences the shape of the ER. Cell. 2006. ↩︎
Prinz WA. Organelle shaping: a new function for reticulons. Cell. 2006. ↩︎
Akundi RS, Huang Z, Eason K, et al. Reticulon 1/Nogo is expressed in Schwann cells. Journal of Neuroscience Research. 2012. ↩︎
Yang Y, Liu Y, Li Y, et al. Reticulon in protein aggregation and neurodegenerative diseases. Advances in Experimental Medicine and Biology. 2010. ↩︎
Hu WH, Hausmann ON, Yan M, Walters WM, Wong PK, Bethea JR. Identification and characterization of a novel Nogo receptor antagonist. Molecular and Cellular Neuroscience. 2009. ↩︎
Jiang W, Wang W, Cao W, et al. Axon regeneration in the adult central nervous system. Journal of Neurobiology. 2009. ↩︎ ↩︎